AMC Q2 Rebound: Revenue, EBITDA Improve But Massive Debt, Interest and Dilution Risk Persist

Company: AMC Entertainment Holdings, Inc. (AMC) - NYSE filing (Form 10‑Q) for quarter ended June 30, 2025. Summary: management is running the business to drive attendance and revenue growth, completed material refinancing steps in July 2025, and continues to rely on equity financings - but the income statement and cash flow still show large losses, heavy interest expense and continued cash burn against a large debt base.

Quick facts - what's happening inside (select items from the 10‑Q)
* Q2 revenue rebound: Total revenues $1,397.9M (Three months ended June 30, 2025) vs $1,030.6M prior year.
* Admissions & attendance: Admissions $762.6M in Q2; attendance Q2 = 62,807 (thousands) (≈62.8M); six‑month attendance = 104,710 (thousands).
* Profitability mix: Q2 operating income $92.6M (Q2 2024 operating loss $(47.4)M); Q2 net loss was $(4.7)M. Six‑month net loss $(206.8)M.
* Adjusted EBITDA: Q2 Adjusted EBITDA $189.2M; six months $131.2M (management's operating performance metric).
* Cash / liquidity: Cash and cash equivalents $423.7M and restricted cash $51.4M - total cash + restricted = $475.1M at June 30, 2025.
* Cash flow & burn: Net cash used in operating activities for six months = $(231.6)M; net decrease in cash & restricted cash for six months = $(205.7)M.
* Debt load: Total principal amount of corporate borrowings $4,097.5M; carrying value of corporate borrowings & finance leases $4,062.3M (June 30, 2025).
* Interest cost: Interest expense three months $129.6M; six months $248.7M - a material drag on results.
* Balance sheet pressure: Total assets $8,173.9M vs total liabilities $9,899.3M → stockholders' deficit $(1,725.4)M.
* Working capital: Working capital deficit (excl. restricted cash) $(963.5)M as of June 30, 2025 (company disclosure).
* Share count / dilution: Shares outstanding as of August 8, 2025 = 512,943,561. Net proceeds from equity issuances during six months = $169.6M (includes ATM and forward activity).
* Major contract development: Amended ESA (NCM) executed April 17, 2025 - term extended through Feb 13, 2042; discount rate used for financing component updated to 16.12% (was ~7.5%).

Recent corporate actions (subsequent events)
* 2025 Refinancing (closed July 24, 2025): New 2029 Notes issued (aggregate $857.0M principal) and New Exchangeable Notes issued (~$194.4M) as part of a package of exchanges and new money ($244.4M incremental financing).
* On July 1, 2025, $143.0M aggregate principal of Existing Exchangeable Notes were exchanged for 79,800,000 shares (immediate dilution). Management used refinancing proceeds to redeem subordinated liens and reduce some near‑term maturities.

Positive aspects of the income statement / operating picture
* Strong top‑line recovery: Revenues up materially year‑over‑year (Q2 +35.6%); admissions and F&B both growing (Q2 admissions $762.6M; F&B $499.6M).
* Operating leverage: Q2 operating income turned positive $92.6M vs loss prior year; Adjusted EBITDA positive and materially improved (Q2 $189.2M).
* Active liquidity actions: Company raised equity (net $169.6M) and completed refinancing steps in July to extend maturities - management is using both equity and debt trades to manage maturity profile.

Negative aspects of the income statement / financial health
* Large reported losses over the year‑to‑date: six‑month net loss $(206.8)M - recurring losses remain significant.
* Massive interest burden: six‑month interest expense $248.7M (pushes operational cash generation to be reinvested in interest); effective finance costs remain very high.
* Cash burn / working capital strain: operating cash outflow $(231.6)M for six months; working capital deficit (excl restricted cash) $(963.5)M.
* Balance‑sheet leverage & deficit: liabilities ($9,899.3M) exceed assets ($8,173.9M); stockholders' deficit $(1,725.4)M - signals continued structural leverage risk.
* Dilution risk: heavy equity issuance activity and note‑for‑equity exchanges (e.g., 79.8M shares issued in July for $143.0M of notes) - potential for more dilution if management raises equity to fund liquidity or settle debt.
* Reliance on film slate / timing: management states revenues must return to pre‑COVID levels for sustainable net positive cash flow - exposure to studios' release calendar, labor actions, and changing distribution dynamics.

What to watch next (near term catalysts / risk monitors)
* Box office trends and attendance vs pre‑COVID benchmarks - sustained revenue momentum is critical.
* Interest expense and actual cash interest paid going forward (impact of July 2025 refinancing on coupon and PIK exposure).
* Progress on shareholder approvals (authorized common shares) and any further equity raises (dilution).
* Execution of New 2029 / New Exchangeable Notes terms (exchange mechanics, soft‑call triggers, and any share issuance to note holders).
* Covenant compliance (company reports compliance at June 30, 2025) and any changes after July refinancing; monitor working capital and cash runway beyond 12 months.

Bottom line: AMC (NYSE: AMC) is showing real top‑line recovery and positive Adjusted EBITDA contribution in Q2, and management has actively reshaped maturities via the July 2025 refinancing and equity issuances. But the company still carries very large debt, a heavy interest burden, negative equity on the balance sheet, significant operating cash outflows and dilution risk - so the path to sustainable profitability depends on continued box‑office strength and successful execution of refinancing and liquidity plans.